TY - JOUR
T1 - Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
AU - Kobayashi, Makoto
AU - Miki, Y.
AU - Ebina, M.
AU - Abe, K.
AU - Mori, K.
AU - Narumi, S.
AU - Suzuki, T.
AU - Sato, I.
AU - Maemondo, M.
AU - Endo, C.
AU - Inoue, A.
AU - Kumamoto, H.
AU - Kondo, Takashi
AU - Yamada-Okabe, H.
AU - Nukiwa, T.
AU - Sasano, H.
N1 - Funding Information:
We appreciate Erina Iwabuchi and Katsuhio Ono (Department of Pathology, Tohoku University School of Medicine) for their skilful technical assistance in cell culture and immunohistochemistry despite enormous damages inflicted upon Tohoku University by the earthquake on 11 March 2012 which interrupted this study. The grant supports were as follows: Grant-in-Aid for Young Scientist (B) and Grant-in-Aid for Scientific Research (B), MEXT, Tokyo, Japan. YM and HS have received research funding from CHUGAI Pharmaceutical Company.
PY - 2012/11/6
Y1 - 2012/11/6
N2 - Background:Lung adenocarcinoma (LADCA) patients with epidermal growth factor receptor (EGFR) mutations are in general associated with relatively high clinical response rate to EGFR-tyrosine kinase inhibitors (TKIs) but not all responded to TKI. It has therefore become important to identify the additional surrogate markers regarding EGFR-TKI sensitivity.Methods:We first examined the effects of EGFR-TKIs, gefitinib and erlotinib, upon cell proliferation of lung adenocarcinoma cell lines. We then evaluated the gene profiles related to EGFR-TKI sensitivity using a microarray analysis. Results of microarray analysis led us to focus on carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family, CEACAM 3, 5, 6, 7, and 19, as potential further surrogate markers of EGFR-TKI sensitivity. We then examined the correlation between the status of CEACAM 3, 5, 6, 7, and 19 immunoreactivity in LADCA and clinicopathological parameters of individual cases.Results:In the cases with EGFR mutations, the status of all CEACAMs examined was significantly higher than that in EGFR wild-type patients, but there were no significant differences in the status of CEACAMs between TKI responder and nonresponder among 22 patients who received gefitinib therapy. However, among 115 EGFR mutation-negative LADCA patients, both CEACAM6 and CEACAM3 were significantly associated with adverse clinical outcome (CEACAM6) and better clinical outcome (CEACAM3).Conclusion: CEACAMs examined in this study could be related to the presence of EGFR mutation in adenocarcinoma cells but not represent the effective surrogate marker of EGFR-TKI in LADCA patients. However, immunohistochemical evaluation of CEACAM3/6 in LADCA patients could provide important information on their clinical outcome.
AB - Background:Lung adenocarcinoma (LADCA) patients with epidermal growth factor receptor (EGFR) mutations are in general associated with relatively high clinical response rate to EGFR-tyrosine kinase inhibitors (TKIs) but not all responded to TKI. It has therefore become important to identify the additional surrogate markers regarding EGFR-TKI sensitivity.Methods:We first examined the effects of EGFR-TKIs, gefitinib and erlotinib, upon cell proliferation of lung adenocarcinoma cell lines. We then evaluated the gene profiles related to EGFR-TKI sensitivity using a microarray analysis. Results of microarray analysis led us to focus on carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family, CEACAM 3, 5, 6, 7, and 19, as potential further surrogate markers of EGFR-TKI sensitivity. We then examined the correlation between the status of CEACAM 3, 5, 6, 7, and 19 immunoreactivity in LADCA and clinicopathological parameters of individual cases.Results:In the cases with EGFR mutations, the status of all CEACAMs examined was significantly higher than that in EGFR wild-type patients, but there were no significant differences in the status of CEACAMs between TKI responder and nonresponder among 22 patients who received gefitinib therapy. However, among 115 EGFR mutation-negative LADCA patients, both CEACAM6 and CEACAM3 were significantly associated with adverse clinical outcome (CEACAM6) and better clinical outcome (CEACAM3).Conclusion: CEACAMs examined in this study could be related to the presence of EGFR mutation in adenocarcinoma cells but not represent the effective surrogate marker of EGFR-TKI in LADCA patients. However, immunohistochemical evaluation of CEACAM3/6 in LADCA patients could provide important information on their clinical outcome.
KW - Carcinoembryonic antigen-related cell adhesion molecule
KW - EGFR inhibitor
KW - Epidermal growth factor receptor (EGFR)
KW - Immunohistochemistry
KW - Lung adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=84869096996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869096996&partnerID=8YFLogxK
U2 - 10.1038/bjc.2012.422
DO - 10.1038/bjc.2012.422
M3 - Article
C2 - 23099808
AN - SCOPUS:84869096996
VL - 107
SP - 1745
EP - 1753
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 10
ER -